文献速递流行病学与生物统计真实世界研究与卫生经济

化疗联合中医药对早期女性乳腺癌患者生存影响的研究方案

Chemotherapy in conjunction with traditional Chinese medicine for survival of patients with early female breast cancer: protocol for a non-randomized, single center prospective cohort study.
PubMed 文献 · Trials · 2019-12-17

这是首个关于早期乳腺癌辅助化疗期间中医药治疗对预后影响的前瞻性观察性队列研究,希望为未来大规模临床试验和整合中医药护理方案提供依据。

要点

  • 本研究为前瞻性观察性队列,非随机对照,旨在评估真实世界中医药联合化疗的预后关联。
  • 计划纳入310例早期乳腺癌术后辅助化疗患者,随访每3-6个月至2023年10月。
  • 主要关注中医药治疗与无病生存的关联,并收集生活质量、副作用、中医体质等信息。

核心结论

  • 研究旨在评估中医药治疗与接受辅助化疗的早期乳腺癌患者无病生存结局的关联。
  • 该研究为未来大规模临床试验和整合中医药护理方案的制定提供可行性依据。

研究设计与样本

  • 计划招募310例早期乳腺癌患者,随访每3至6个月,至2023年10月。

局限性

  • 非随机设计可能引入选择偏倚,难以确立因果关系。
  • 单中心研究可能限制结果的外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemotherapy after surgery for breast cancer plays a fundamental role in reducing the risk of distant and local recurrence. An increasing number of patients seek traditional Chinese medicine (TCM) during adjuvant chemotherapy to relieve symptom discomfort and side effects as well as to strengthen the body's defenses. However, evidence on how concurrent TCM treatment affects prognosis is scarce. This trial aims to evaluate the association between TCM treatment and disease-free survival outcomes for patients with early breast cancer who are undergoing adjuvant chemotherapy. METHODS/DESIGN: This is a non-randomized, single center, prospective cohort study begun in November 2018 in Kaohsiung, Taiwan. A sample of 310 participants diagnosed with early breast cancer was recruited from the Breast Cancer Research Team and will be followed up every 3 to 6 months until October 2023. Detailed information of the participants, including general information, history of cancer, quality of life, side effects and safety of treatment, TCM body constitution, and meridian energy analysis, was collected face to face at baseline. DISCUSSION: This is the first prospective observational cohort study on TCM in patients with early breast cancer who are receiving adjuvant chemotherapy to evaluate the prognosis. Through this trial, we hope to assess the feasibility of a larger-scale clinical trial in the future and formulate an integrated TCM care program. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03797248. Registered on 5 January 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Liu CT, Chen YH, Huang YC, et al. Chemotherapy in conjunction with traditional Chinese medicine for survival of patients with early female breast cancer: protocol for a non-randomized, single center prospective cohort study. Trials. 2019. PMID: 31847861. doi:10.1186/s13063-019-3848-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。